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The pathogenesis of osteonecrosis in sickle cell anemia (SCA) remains unknown. Blood 
hyper-viscosity has been suggested as a factor involved in the genesis of osteonecrosis1, but 
not studied until now. We hypothesized that abnormal hemorheology could play a role in this 
complication. Hematological and hemorheological parameters were assessed in SCA patients 
with osteonecrosis (OST+, n=30) or without (OST-, n=67). Osteonecrosis was diagnosed as 
previously described2. The study was conducted according to the Declaration of Helsinki 
guidelines, and was approved by the Regional Ethics Committee. The results are reported in 
the table. OST+ patients were older than OST- (p < 0.05) and more had a history of vaso-
occlusive crises (VOC) within the previous year (p < 0.05) and a higher frequency of -
thalassemia (p < 0.05), confirming previous studies3-5. Although the OST+ group exhibited 
higher Hb and Hct, and lower hemolytic component than the OST- group (p < 0.01), blood 
viscosity was not significantly different between the two groups (p < 0.20). In contrast, red 
blood cell (RBC) deformability (p < 0.001) and aggregation (p < 0.05) were increased in the 
OST+ group. The hydroxyurea (HU) treatment frequency was not significantly different 
between the two groups (p < 0.20). As HU is known to modulate RBC deformability6, we 
analyzed the data as a function of HU therapy independently of osteonecrosis, and found that 
HU-treated patients had lower blood viscosity and greater RBC deformability (data not 
shown). Excluding HU-treated patients from the cohort did not change the results (table).  
A binary (OST-/OST+) multivariate logistic model was used to identify factors associated 
with osteonecrosis in SCA patients, and included age, Hb, RBC aggregation and 
deformability, hemolytic component, -thalassemia status and previous history of VOC as 
covariates. The overall model was significant (chi-square=30.192; df=7; p<0.0001), and 
retained age (OR: 1.06; 95% CI 1.01-1.12; p<0.05), Hb (OR: 2.24; 95% CI 1.19-4.18; 
p<0.05) and RBC deformability (OR: 1.15; CI 1.01-1.33; p<0.05) as independent factors 
statistically associated with osteonecrosis. Two other binary multivariate logistic models were 
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tested; one included the previous parameters plus blood viscosity and HU therapy, and the 
other excluded all HU patients. The results were similar to those in the first model (data not 
shown).  
Our study demonstrates that increased RBC deformability is associated with osteonecrosis in 
SCA. Irregularly shaped, deformable sickle RBC were previously shown to be more adherent 
than rigid, irreversibly sickle RBC,7 hence triggering vascular occlusion.8 The greater RBC 
deformability found in the OST+ group is probably due to the greater frequency of -
thalassemia patients in this group since patients with -thalassemia had greater RBC 
deformability (0.18±0.05) than patients without (0.15±0.06, p<0.05). Even though higher Hb 
levels were observed in patients with osteonecrosis, the data do not support a significant role 
for blood viscosity in the pathogenesis of this complication, even after excluding data from 
patients under HU therapy. Further studies will be required to delineate the mechanisms by 
which RBC deformability raise the risk for osteonecrosis.   
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Table 1: General characteristics, hematological and hemorheological parameters  
 With patients under HU  Without patients under HU  
 OST- (67) OST+ (30) OST- (57) OST+ (22) 
Age (yrs) 32.5 ± 12.2 39.3 ± 13.1* 32.0 ± 12.4 38.8 ± 11.9* 
Sex (M/F) 32/35 11/19 27/30 9/13 
HU (%) 15.9 27.6 - - 
-thalassemia (%) 37.3 56.7* 40.4 59.1 
Positive history of 
VOC (%) 
9.0 26.7* 8.8 27.3* 
HbF (%) 7.9 ± 5.7 9.6 ± 6.2 7.5 ± 5.6 9.1 ± 6.1 
WBC (10
9
/l) 9.5 ± 2.0 8.7 ± 2.1 10.0 ± 2.7 9.0 ± 1.7 
RBC (10
12
/l) 2.8 ± 0.6 2.9 ± 0.5 2.8 ± 0.6 3.1 ± 0.4 
PLT (10
9
/l) 404 ± 126 381 ± 136 414 ± 125 373 ± 144 
MCV (fl) 83.5 ± 9.8 86.6 ± 10.1 81.4 ± 8.2 83.5 ± 7.4 
MCHC (g/dl) 35.9 ± 1.1 35.6 ± 1.2 35.8 ± 1.1 35.5 ± 1.3 
Hb (g/dl) 8.2 ± 1.3 9.0 ±1.1** 8.1 ± 1.2  9.1 ± 1.1*** 
Hct (%) 22.9 ± 3.7 25.2 ± 3.0** 22.7 ± 3.4 25.6 ± 3.1*** 
RET (%) 8.5 ± 3.3 7.7 ± 2.7 8.6 ± 3.3 7.7 ± 2.3 
BIL (mol/l) 61.9 ± 44.1 52.6 ± 37.4 62.8 ± 46.1 54.7 ± 43.0 
AST (IU/l) 39.4 ± 14.8 37.0 ± 10.1 39.8 ± 14.3 37.1 ± 11.2 
LDH (IU/l) 522 ± 166 433 ± 96** 537 ± 161 442 ± 100** 
Hemolytic component 
(relative unit) 
0.16 ± 1.10 -0.35 ± 0.61** 0.23 ± 1.08 -0.33 ± 0.61** 
b (mPa.s-1) 7.64 ± 1.79 8.24 ± 2.01 7.80 ± 1.75 8.40 ± 2.16 
RBC deformability at 15 ± 6 20 ± 5*** 15 ± 5 19 ± 5*** 
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3 Pa (a.u.*100) 
RBC aggregation (%) 52 ± 9 57 ± 8* 52 ± 10 55 ± 7 
RBC disaggregation 
threshold (s
-1
) 
306 ± 148 262 ± 108 309 ± 152 265 ± 116 
Means ± SD. All patients were at steady state at the time of the study, i.e., no blood 
transfusions in the previous three months and absence of acute episodes at least two months 
before inclusion into the study. Measurements of four hemolytic markers (bilirubin, BIL; 
lactate dehydrogenase, LDH; aspartate aminotransferase, AST; reticulocytes, RET) were 
performed using standard methods, and a principal component analysis was used to derive a 
hemolytic component value from these markers.
9
 This standard statistical data reduction 
approach uses conventional clinical measurements to explain the maximum-shared variance 
among these indirect measures of hemolysis. The hemolytic component has recently been 
demonstrated to reflect intravascular hemolysis
9
 and had a mean of 0 (SD = 1.0), and 
predicted 49.2% of the variation among all four measured variables (Eigenvalue = 1.97). 
Blood viscosity, red blood cell (RBC) deformability and aggregation properties were 
determined as previously described.
10
 Polymerase Chain Reaction (Gap-PCR) was used to 
detect the 6 common -thalassemia deletions, including -3.7 and -4.2 alleles, and triplication 
defects of the -globin genes. HU, hydroxyurea therapy; VOC, vaso-occlusive crisis; HbF, 
fetal hemoglobin; WBC, white blood cells; RBC, red blood cells; PLT, platelets; MCV, mean 
cell volume; MCHC, mean corpuscular hemoglobin concentration; Hb, hemoglobin; Hct, 
hematocrit; b, blood viscosity; RBC, red blood cell. Significant difference between the two 
groups: *p < 0.05; **p < 0.01; ***p < 0.001. 
 
 
 
